pravastatin has been researched along with folic acid in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Dobs, AS; Sarma, PS; Wilder, L | 1 |
| Constans, J | 1 |
| Johnson, RA | 1 |
| Dubská, L; Dvoráková, J; Hyánek, J; Táborský, L | 1 |
| Császár, A; Márk, L | 1 |
| Schück, O; Stollová, M; Teplan, V; Vítko, S | 1 |
| Nanayakkara, PW; Scheffer, PG; Stehouwer, CD; Teerlink, T; ter Wee, PM; Twisk, JW; van Dorp, W; van Guldener, C; van Ittersum, FJ | 1 |
| Hasui, S; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Yasuda, S | 1 |
| Kiefte-de Jong, JC; Nanayakkara, PW; Olthof, MR; Smulders, YM; Stehouwer, CD; Teerlink, T; ter Wee, PM; Twisk, JW; van Guldener, C; van Ittersum, FJ | 1 |
| Bu, X; Li, C; Liu, Y | 1 |
2 review(s) available for pravastatin and folic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6 | 2002 |
5 trial(s) available for pravastatin and folic acid
| Article | Year |
|---|---|
Lipid-lowering diets in patients taking pravastatin, a new HMG-CoA reductase inhibitor: compliance and adequacy.
Topics: Adult; Aged; Anticholesteremic Agents; Calcium, Dietary; Diet Records; Dietary Fats; Double-Blind Method; Energy Intake; Female; Folic Acid; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Male; Middle Aged; Naphthalenes; Patient Compliance; Pravastatin; Pyridoxine; Vitamin D; Zinc | 1991 |
Broader use of lipid-lowering therapy argued.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Folic Acid; Humans; Male; Middle Aged; Pravastatin; Pyridoxine; Risk Factors; Survival Analysis | 1999 |
[Effect of hypolipemic agents on levels of total plasma homocysteine].
Topics: Adolescent; Adult; Aged; Cholesterol; Female; Folic Acid; Homocysteine; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Vitamin B 12; Vitamin B 6 | 2001 |
Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxid
Topics: Administration, Oral; Carotid Artery, Common; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Folic Acid; Follow-Up Studies; Glomerular Filtration Rate; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Pravastatin; Pyridoxine; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Ultrasonography; Vitamin E; Vitamins | 2007 |
Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
Topics: Adult; Aged; Anticholesteremic Agents; Arginine; Carotid Arteries; Chronic Disease; Creatinine; Double-Blind Method; Female; Folic Acid; Homocysteine; Humans; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Vitamin B 12; Vitamin B 6; Vitamin E | 2009 |
8 other study(ies) available for pravastatin and folic acid
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
[Atherosclerosis. Congress of the European Atherosclerosis Society (EAS), Athens (Greece), 26-29 May 1999].
Topics: Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Ascorbic Acid; Cholesterol, LDL; Diet; Europe; Folic Acid; Greece; Humans; Hyperhomocysteinemia; Lipoproteins; Pravastatin; Pyridoxine; Risk Factors; Societies, Medical; Triglycerides | 1999 |
Obesity and hyperhomocysteinaemia after kidney transplantation.
Topics: Adult; Aged; Cohort Studies; Combined Modality Therapy; Diet Therapy; Drug Therapy, Combination; Female; Folic Acid; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Hyperhomocysteinemia; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Obesity; Postoperative Complications; Pravastatin; Probability; Prospective Studies; Risk Assessment; Treatment Outcome; Vitamin B 6 | 2003 |
The mechanism of carrier-mediated transport of folates in BeWo cells: the involvement of heme carrier protein 1 in placental folate transport.
Topics: Base Sequence; Biological Transport; Carrier Proteins; Cell Line, Tumor; DNA Primers; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Hydrogen-Ion Concentration; Kinetics; Membrane Transport Proteins; Placenta; Pravastatin; Proton-Coupled Folate Transporter; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiamine Pyrophosphate | 2008 |
Effect of folic acid combined with pravastatin on arteriosclerosis in elderly hypertensive patients with lacunar infarction.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Blood Pressure; Carotid Intima-Media Thickness; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Folic Acid; Humans; Hypertension; Lipids; Male; Middle Aged; Pravastatin; Stroke, Lacunar | 2021 |